Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation

CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic leukemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated with ARI-0001 CART19 cells, six of them with Richter's transformation (RT). One patient with RT never received thera...

ver descrição completa

Detalhes bibliográficos
Autores: Ortiz-Maldonado, Valentín|||0000-0003-4699-6862, Frigola, Gerard|||0000-0001-6794-6456, Español-Rego, Marta|||0000-0001-5497-2276, Balagué, Olga|||0000-0002-5099-3675, Martínez Cibrián, Núria|||0000-0002-8688-1202, Magnano, Laura|||0000-0002-6928-8386, Giné, Eva|||0000-0002-0532-1204, Pascal, Mariona|||0000-0003-0549-9720, Correa, Juan G., Martínez-Roca, Alexandra|||0000-0003-2143-5356, Cid, Joan|||0000-0001-5445-4508, Lozano, Miquel|||0000-0003-2593-833X, Villamor, Neus|||0000-0001-6538-4111, Benítez Ribas, Daniel|||0000-0002-2346-5324, Esteve Reyner, Jordi|||0000-0002-8056-648X, López Guillermo, Armando|||0000-0002-8588-8381, Campo, Elias|||0000-0001-9850-9793, Urbano Ispizua, Álvaro|||0000-0002-7529-9399, Juan, Manel|||0000-0002-3064-1648, Delgado, Julio|||0000-0002-5157-4376
Tipo de documento: artigo
Data de publicação:2022
País:España
Recursos:Universitat Autònoma de Barcelona
Repositório:Dipòsit Digital de Documents de la UAB
Idioma:inglês
OAI Identifier:oai:ddd.uab.cat:270599
Acesso em linha:https://ddd.uab.cat/record/270599
https://dx.doi.org/urn:doi:10.3389/fonc.2022.828471
Access Level:Acceso aberto
Palavra-chave:CLL
CART
CD19
DLBCL
Richter disease
Descrição
Resumo:CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic leukemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated with ARI-0001 CART19 cells, six of them with Richter's transformation (RT). One patient with RT never received therapy. The cytokine release syndrome rate was 87.5% (12.5% grade ≥3). Neurotoxicity was not observed in any patient. All patients experienced absolute B-cell aplasia, and seven (87.5%) responded to therapy. With a median follow-up of 5.6 months, two patients with RT experienced a CD19-negative relapse. In conclusion, ARI-0001 cell therapy was feasible, safe, and effective in patients with high-risk CLL or RT.

Registros relacionados